Biotech Stock SLS Surges 15% on REGAL Trial Buzz
H+Headlines PlusAutoCompiled automatically from 1 source · updated about 2 hours ago
In This StoryAuto-extracted · NER + AI entities
Organizations
SLSellas Life Sciences
Topics
Clinical Trial Results
AI Summary · generated from 1 source
Sellas Life Sciences is drawing serious retail investor attention as traders anticipate a major catalyst from the REGAL Phase 3 trial. The stock jumped 15% as the market eyes potential positive results. The biotech company's shares are gaining momentum among retail traders on Stocktwits, signaling growing confidence in the clinical trial outcome. This kind of retail-driven rally often precedes significant company announcements or data releases.
Sellas Life SciencesClinical Trial Results
Sources · 0 covering this story
More Across Headlines Plus
Discussion



